orabloc 1:200.000 40 mg/ml+0,005 mg/ml
pierrel s.p.a. - italia - combinatii (articainum+adrenalinum) - sol. inj. - 40mg/ml+0,005mg/ml - anestezice locale amide
milnacipran pierre fabre medicament
pierre fabre medicament - milnacipran - fibromialgia
orabloc 1:200.000 40 mg/0,005 mg/ml soluţie injectabilă
pierrel s.p.a. - articainum + epinephrinum - soluţie injectabilă - 40 mg/0,005 mg/ml
orabloc 1:100.000 40 mg/0,01 mg/ ml soluţie injectabilă
pierrel s.p.a. - articainum + epinephrinum - soluţie injectabilă - 40 mg/0,01 mg/ ml
braftovi 50 mg
pierre fabre medicament production - franta - encorafenibum - caps. - 50mg - inhibitori de protein-kinaza antineoplazice
braftovi 75 mg
pierre fabre medicament production - franta - encorafenibum - caps. - 75mg - inhibitori de protein-kinaza antineoplazice
mektovi 15 mg
pierre fabre mÉdicament production - franta - binimetinibum - compr. film. - 15mg - alte antineoplazice inhibitori de protein-kinaza
impulsor
pierre fabre medicament - milnacipran - fibromialgia
ebvallo
pierre fabre medicament - tabelecleucel - lymphoproliferative disorders - ebvallo is indicated as monotherapy for treatment of adult and paediatric patients 2 years of age and older with relapsed or refractory epstein-barr virus positive post-transplant lymphoproliferative disease (ebv+ ptld) who have received at least one prior therapy. for solid organ transplant patients, prior therapy includes chemotherapy unless chemotherapy is inappropriate.
mektovi
pierre fabre medicament - binimetinib - melanomul - agenți antineoplazici - binimetinib în combinație cu encorafenib este indicat pentru tratamentul pacienților adulți cu melanom inoperabil sau metastatic cu mutația braf v600.